RAPT Therapeutics, Inc.
RAPT
$32.01
-$0.32-0.99%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.91% | 3.95% | 2.02% | 10.84% | 11.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.93% | -12.35% | -4.04% | 7.11% | -2.89% |
| Operating Income | 1.93% | 12.35% | 4.04% | -7.11% | 2.89% |
| Income Before Tax | 1.73% | 11.58% | 1.30% | -11.19% | 1.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.73% | 11.58% | 1.30% | -11.19% | 1.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.73% | 11.58% | 1.30% | -11.19% | 1.27% |
| EBIT | 1.93% | 12.35% | 4.04% | -7.11% | 2.89% |
| EBITDA | 1.72% | 12.31% | 4.01% | -7.19% | 3.00% |
| EPS Basic | 50.23% | 43.16% | 21.69% | -2.29% | 3.64% |
| Normalized Basic EPS | 50.72% | 43.72% | 22.66% | -1.19% | 3.53% |
| EPS Diluted | 50.23% | 43.16% | 21.69% | -2.29% | 3.64% |
| Normalized Diluted EPS | 50.72% | 43.72% | 22.66% | -1.19% | 3.53% |
| Average Basic Shares Outstanding | 347.99% | 234.94% | 121.13% | 6.35% | 2.74% |
| Average Diluted Shares Outstanding | 347.99% | 234.94% | 121.13% | 6.35% | 2.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |